Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy

作者全名："Fan, Rong; Niu, Junqi; Ma, Hong; Xie, Qing; Cheng, Jun; Rao, Huiying; Dou, Xiaoguang; Xie, Jianping; Zhao, Wei; Peng, Jie; Gao, Zhiliang; Gao, Hongbo; Chen, Xinyue; Chen, Jinjun; Li, Qiang; Tang, Hong; Zhang, Zhengang; Ren, Hong; Cheng, Mingliang; Liang, Xieer; Zhu, Chaonan; Wei, Lai; Jia, Jidong; Sun, Jian; Hou, Jinlin"

作者地址："[Fan, Rong; Liang, Xieer; Hou, Jinlin] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res,Guangdong Prov Ke, Guangzhou, Peoples R China; [Ma, Hong] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing 100050, Peoples R China; [Fan, Rong; Liang, Xieer; Hou, Jinlin] Southern Med Univ, Shenzhen Hosp, Hepatol Unit, Shenzhen, Peoples R China; [Niu, Junqi] 1 Hosp Jilin Univ, Hepatol Unit, Changchun, Peoples R China; [Xie, Qing] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Infect Dis, Sch Med, Shanghai, Peoples R China; [Cheng, Jun] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China; [Rao, Huiying] Peking Univ, Peking Univ Peoples Hosp, Hepatol Inst, Beijing, Peoples R China; [Dou, Xiaoguang] China Med Univ, Dept Infect Dis, Shengjing Hosp, Shenyang, Peoples R China; [Xie, Jianping] Cent South Univ, Xiangya Hosp, Dept Infect Dis, Changsha, Peoples R China; [Zhao, Wei] Second Hosp Nanjing, Nanjing, Peoples R China; [Gao, Zhiliang] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou, Peoples R China; [Gao, Hongbo] 8th Peoples Hosp, Guangzhou, Peoples R China; [Chen, Xinyue] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China; [Li, Qiang] Jinan Infect Dis Hosp, Jinan, Peoples R China; [Tang, Hong] West China Hosp, Dept Infect Dis, Chengdu, Peoples R China; [Zhang, Zhengang] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan, Peoples R China; [Ren, Hong] Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Chongqing, Peoples R China; [Cheng, Mingliang] Guizhou Med Univ, Dept Infect Dis, Affiliated Hosp, Guiyang, Peoples R China; [Zhu, Chaonan] Hangzhou YITU Healthcare Technol Co Ltd, Big Data Res & Biostat Ctr, Hangzhou, Peoples R China; [Wei, Lai] Tsinghua Univ, Hepatopancreatobiliary Ctr, Sch Clin Med, Beijing Tsinghua Changgung Hosp, Beijing, Peoples R China; [Wei, Lai] Peking Univ, Peking Univ Peoples Hosp, Inst Hepatol, Beijing, Peoples R China"

通信作者："Sun, J; Hou, JL (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res,Guangdong Prov Ke, Guangzhou, Peoples R China.; Jia, JD (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing 100050, Peoples R China."

来源：ALIMENTARY PHARMACOLOGY & THERAPEUTICS

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:000664264900001

JCR分区：Q1

影响因子：7.6

年份：2021

卷号：54

期号：3

开始页：329

结束页：338

文献类型：Article

关键词：　

摘要："Background Obesity is typically associated with metabolic dysfunction, but its impact on hepatocellular carcinoma (HCC) remains unclear in patients with chronic hepatitis B (CHB). Aim To study the effect of obesity on HCC development in patients with CHB receiving antiviral therapy. Methods We included patients from a Chinese multicentre, prospective, observational, treated CHB cohort in this study. General obesity was evaluated by body-mass index (BMI). Central obesity was evaluated by waist circumference, waist-to-hip ratio and waist-to-height ratio. Results A total of 5754 nucleos(t)ide analogue treated patients were enrolled in the analysis. The 5-year cumulative incidence of HCC was 2.9%. Waist-to-height ratio performed better in predicting HCC development than BMI, waist circumference or waist-to-hip ratio. Patients with central obesity (defined as waist-to-height ratio >0.5) had significantly higher 5-year incidence of HCC than those without central obesity in the overall population (3.9% vs 2.1%, hazard ratio [HR]: 2.06, P = 0.0001) and 745 propensity score matched pairs (4.7% vs 2.3%, HR: 2.04, P = 0.026), respectively. Besides cirrhosis status and aMAP HCC risk score, central obesity was also independently associated with HCC risk (HR: 1.63, P = 0.013). Waist-to-height ratio gain within 1 year was associated with a significantly higher HCC risk with an adjusted HR value of 1.88 (95% confidence interval: 1.12-3.13, P = 0.017). Conclusions Central obesity, evaluated by the waist-to-height ratio, was associated with a twofold increase in HCC risk among CHB patients receiving antiviral treatment, highlighting the important role of abnormal metabolic function in the progression of liver disease."

基金机构："National Major S cience and Technology Projects of China [2017ZX10202202, 2018ZX10301202]; Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program [2017BT01S131]; Sanming Project of Medicine in Shenzhen [SZSM201911001]"

基金资助正文："National Major S cience and Technology Projects of China, Grant/Award Number: 2017ZX10202202 and 2018ZX10301202; Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program, Grant/Award Number: 2017BT01S131; Sanming Project of Medicine in Shenzhen, Grant/Award Number: SZSM201911001"